
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1508233/publications.pdf Version: 2024-02-01



IOSHUA LEIELD

#	Article	IF	CITATIONS
1	Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, openâ€ l abel study. American Journal of Hematology, 2022, 97, 691-699.	4.1	19
2	lleitis in Adult Multisystem Inflammatory Syndrome: A Case Report. , 2022, 1, .		0
3	Social and Psychological Factors Associated With Health Care Transition for Young Adults Living With Sickle Cell Disease. Journal of Transcultural Nursing, 2021, 32, 21-29.	1.3	9
4	Gaps in the diagnosis and management of iron overload in sickle cell disease: a â€~realâ€world' report from the GRNDaD registry. British Journal of Haematology, 2021, 195, e157-e160.	2.5	4
5	Treatment of Acute Pain in Adults With Sickle Cell Disease in an Infusion Center Versus the Emergency Department. Annals of Internal Medicine, 2021, 174, 1207-1213.	3.9	16
6	American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Advances, 2020, 4, 327-355.	5.2	241
7	Chronic pain persists in adults with sickle cell disease despite regular red cell transfusions. Transfusion and Apheresis Science, 2019, 58, 434-438.	1.0	7
8	Contrast-enhanced ultrasound detects changes in microvascular blood flow in adults with sickle cell disease. PLoS ONE, 2019, 14, e0218783.	2.5	9
9	Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. Annals of the American Thoracic Society, 2019, 16, e17-e32.	3.2	33
10	The controversial role of red cell transfusions for sickle cell pain. Current Opinion in Hematology, 2019, 26, 442-447.	2.5	1
11	AAAPT Diagnostic Criteria for Acute Sickle Cell Disease Pain. Journal of Pain, 2019, 20, 746-759.	1.4	37
12	Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study. Blood, 2019, 134, 3518-3518.	1.4	3
13	Chronic Kidney Disease Is Under-Screened in SCD and Mild Albuminuria Is Associated with a Drop in Hemoglobin: A Report from the Grndad Sickle Cell Registry. Blood, 2019, 134, 2284-2284.	1.4	0
14	Dyspareunia is associated with chronic pain in premenopausal women with sickle cell disease. Hematology, 2018, 23, 531-536.	1.5	3
15	Increased acute care utilization in a prospective cohort of adults with sickle cell disease. Blood Advances, 2018, 2, 2412-2417.	5.2	31
16	Predictive factors of daily opioid use and quality of life in adults with sickle cell disease. Hematology, 2018, 23, 856-863.	1.5	21
17	Induction of antiinflammatory purinergic signaling in activated human iNKT cells. JCI Insight, 2018, 3, .	5.0	14
18	Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study. Blood, 2018, 132, 3612-3612.	1.4	6

#	Article	IF	CITATIONS
19	Iron Overload Is Under-Recognized and Under-Treated in SCD: A Report from the Grndad Registry. Blood, 2018, 132, 158-158.	1.4	0
20	Patient Satisfaction of Care in the Treatment of Vaso-Occlusive Crises: A Comparison of Emergency Department and Infusion Centers in the Escaped Study. Blood, 2018, 132, 314-314.	1.4	0
21	A Five Fold Decrease in Admissions for Uncomplicated Vaso-Occlusive Crisis and Other Benefits from Care in Infusion Clinics: Results from the Escaped Trial. Blood, 2018, 132, 853-853.	1.4	1
22	Older red cell units are associated with an increased incidence of infection in chronically transfused adults with sickle cell disease. Transfusion and Apheresis Science, 2017, 56, 345-351.	1.0	9
23	Augmentation of Muscle Blood Flow by Ultrasound Cavitation Is Mediated by ATP and Purinergic Signaling. Circulation, 2017, 135, 1240-1252.	1.6	82
24	A novel process to extract important information from invisible video captured by smartphone. , 2017, , .		0
25	Airway Hyperresponsiveness Does Not Predict Morbidity in Children with Sickle Cell Anemia. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1533-1534.	5.6	3
26	Bild (big image in less dimension): A novel technique for image feature selection to apply partial least square algorithm. , 2017, , .		0
27	Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. Blood Advances, 2017, 1, 1645-1649.	5.2	38
28	NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease. PLoS ONE, 2017, 12, e0171067.	2.5	30
29	A Fatal Case of Immune Hyperhemolysis with Bone Marrow Necrosis in a Patient with Sickle Cell Disease. Hematology Reports, 2017, 9, 8-11.	0.8	6
30	Increased circulating fibrocytes are associated with higher reticulocyte percent in children with sickle cell anemia. Pediatric Pulmonology, 2016, 51, 295-299.	2.0	2
31	Maternal opioid dose is associated with neonatal abstinence syndrome in children born to women with sickle cell disease. American Journal of Hematology, 2016, 91, 416-419.	4.1	12
32	Red cell storage age policy for patients with sickle cell disease: A survey of transfusion service directors in the United States. Transfusion and Apheresis Science, 2016, 54, 158-162.	1.0	4
33	Can selectin and iNKT cell therapies meet the needs of people with sickle cell disease?. Hematology American Society of Hematology Education Program, 2015, 2015, 426-432.	2.5	7
34	Sickle solubility test to screen for sickle cell trait: what's the harm?. Hematology American Society of Hematology Education Program, 2015, 2015, 433-435.	2.5	6
35	Intensive management of highâ€utilizing adults with sickle cell disease lowers admissions. American Journal of Hematology, 2015, 90, 215-219.	4.1	28
36	A case of acute chest syndrome complicated by diffuse cerebral infarcts in an adult with <scp>H</scp> b <scp>S</scp> l²â€thalassemia ⁺ . American Journal of Hematology, 2015, 90, E197.	4.1	0

#	Article	IF	CITATIONS
37	Use of a dual lumen port for automated red cell exchange in adults with sickle cell disease. Journal of Clinical Apheresis, 2015, 30, 353-358.	1.3	27
38	Erythropoietic drive is the strongest predictor of hepcidin level in adults with sickle cell disease. Blood Cells, Molecules, and Diseases, 2015, 55, 304-307.	1.4	19
39	NKTT120 Safely Depletes iNKT Cells in Stable Adult Sickle Cell Patients in a Phase 1 Trial. Blood, 2015, 126, 2178-2178.	1.4	0
40	Advances in Sickle Cell Therapies in the Hydroxyurea Era. Molecular Medicine, 2014, 20, S37-S42.	4.4	18
41	The Role of Adenosine Signaling in Sickle Cell Therapeutics. Hematology/Oncology Clinics of North America, 2014, 28, 287-299.	2.2	24
42	Children with Sickle Cell Disease on Chronic Red Cell Transfusion Experience Fewer Hospitalizations for Acute Vaso-Occlusive Episodes Irrespective of the Indication for Transfusion. Blood, 2014, 124, 4282-4282.	1.4	0
43	Contrast-Enhanced Ultrasound Detects Differences in Microvascular Blood Flow in Adults with Sickle Cell Disease Administered Regadenoson. Blood, 2014, 124, 2705-2705.	1.4	23
44	Higher Levels of Circulating Fibrocytes Are Associated with Lower Oxygen Saturation in Adults with Sickle Cell Disease. Blood, 2014, 124, 2710-2710.	1.4	0
45	Death during an asthma exacerbation in an adult with sickle cell disease: An autopsy case study. American Journal of Hematology, 2013, 88, 824-824.	4.1	6
46	Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood, 2013, 121, 3329-3334.	1.4	87
47	Environmental Tobacco Smoke and Airway Obstruction in Children With Sickle Cell Anemia. Chest, 2013, 144, 1323-1329.	0.8	17
48	NF-κB Activation Mediates Induction Of Anti-Inflammatory Adenosine A2A Receptors In iNKT Cells Of Sickle Cell Patients During Vaso-Occlusive Episodes and Upon Activation Of Cultured Human iNKT Cells. Blood, 2013, 122, 975-975.	1.4	0
49	Sickle cell disease: new treatments and their rationale. Clinical Advances in Hematology and Oncology, 2013, 11, 740-3.	0.3	1
50	Recurrent, severe wheezing is associated with morbidity and mortality in adults with sickle cell disease. American Journal of Hematology, 2011, 86, 756-761.	4.1	54
51	Airway Hyperresponsiveness in Children With Sickle Cell Anemia. Chest, 2011, 139, 563-568.	0.8	81
52	Asthma and sickle cell disease: two distinct diseases or part of the same process?. Hematology American Society of Hematology Education Program, 2009, 2009, 45-53.	2.5	49
53	Urinary cysteinyl leukotriene E ₄ is associated with increased risk for pain and acute chest syndrome in adults with sickle cell disease. American Journal of Hematology, 2009, 84, 158-160.	4.1	26
54	Urinary cysteinyl leukotriene E ₄ significantly increases during pain in children and adults with sickle cell disease. American Journal of Hematology, 2009, 84, 231-233.	4.1	32

#	Article	IF	CITATIONS
55	Acute pain in children and adults with sickle cell disease: management in the absence of evidence-based guidelines. Current Opinion in Hematology, 2009, 16, 173-178.	2.5	35
56	NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-1 ³ and CXCR3 chemokines. Blood, 2009, 114, 667-676.	1.4	149
57	Growth of lung function in children with sickle cell anemia. Pediatric Pulmonology, 2008, 43, 1061-1066.	2.0	31
58	Longitudinal analysis of pulmonary function in adults with sickle cell disease. American Journal of Hematology, 2008, 83, 574-576.	4.1	50
59	Sibling history of asthma is a risk factor for pain in children with sickle cell anemia. American Journal of Hematology, 2008, 83, 855-857.	4.1	18
60	Enuresis Is a Common and Persistent Problem Among Children and Young Adults with Sickle Cell Anemia. Urology, 2008, 72, 81-84.	1.0	26
61	Risk Factors for Primary Hemorrhagic Stroke in Adults with Sickle Cell Disease Blood, 2007, 110, 3809-3809.	1.4	Ο
62	Low Frequency of Telomerase RNA Mutations Among Children With Aplastic Anemia or Myelodysplastic Syndrome. Journal of Pediatric Hematology/Oncology, 2006, 28, 450-453.	0.6	27
63	Immunosuppressive Therapy for Acute Porphyria: Safety and Efficacy in a Patient with Bone Marrow Failure. Pharmacotherapy, 2006, 26, 1662-1666.	2.6	2